- Title: Subtitle
- Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors
- Creators
- Jonathan R. Strosberg - Moffitt Cancer CenterEdward M. Wolin - University of KentuckyBeth A. Chasen - The University of Texas MD Anderson Cancer CenterMatthew H. Kulke - Boston Medical CenterDavid L Bushnell - University of IowaMartyn E. Caplin - The Royal Free HospitalRichard P. Baum - Zentralklinik Bad BerkaTimothy J. Hobday - Mayo ClinicAndrew Eugene Hendifar - Cedars-Sinai Medical CenterLaura Ravasi - Advanced Accelerator ApplicationsKjell E. Oberg - Uppsala University HospitalPhilippe B. Ruszniewski - Délégation Paris 7Eric Krenning - Erasmus MC
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.4102-4102
- DOI
- 10.1200/JCO.2018.36.15_suppl.4102
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Radiology
- Record Identifier
- 9984320090602771
Abstract
Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors
Journal of clinical oncology, Vol.36(15_suppl), pp.4102-4102
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.4102
Details
Metrics
1 Record Views